Unique Anti-microbial Rinse to Reduce Oral Inflammation

独特的抗菌冲洗剂可减少口腔炎症

基本信息

  • 批准号:
    7928457
  • 负责人:
  • 金额:
    $ 41.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-01 至 2013-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Periodontal disease has been recently identified as a risk factor for increased morbidity and mortality for systemic diseases such as pancreatic cancer, cardiovascular disease (atherosclerosis, myocardial infarction, and stroke), and diabetes, as well as for pregnancy complications such as preterm birth. It is well established that periodontal disease results from microorganisms in dental plaque biofilm. Inflammatory reactions initiated by oral bacteria and their components are implicated locally in the pathogenesis of periodontal tissue destruction, and may contribute to the development of systemic disease. While causality has yet to be confirmed, some studies have shown that oral health interventions may impact biological markers of inflammation and disease. The goal of this project is to develop a prescription antimicrobial oral rinse to reduce bacterial bioburden in the oral cavity and combat oral disease and inflammation. Current oral rinse products are either fraught with side effects such as staining and taste alterations that limit their usage to acute settings, or are ineffective. Based on preliminary studies, the oral rinse developed herein is expected to be more effective than currently available prescription products without the side effects. The development of a highly effective oral rinse may have the potential to have a profound impact on public health and achieve significant commercial success. This study is a Fast-Track proposal that combines both Phase I and Phase II studies in one application. The Phase I portion has two Specific Aims: Aim 1. Compound Oral Rinse Formulations for Use in Clinical Trials Aim 2. Evaluate Dose-Response of the Oral Rinse in a Human Clinical Trial of Gingival Inflammation and Investigate Effects on Biological Markers Indicative of Systemic Disease. The Phase II portion has three Specific Aims: Aim 1. Compound Oral Rinse Formulations for Use in Clinical Trials Aim 2. Evaluate the Oral Rinse in a Human Clinical Trial of Gingivitis to Satisfy FDA Requirements and Investigate Effects on Biological Markers Indicative of Systemic Disease. PUBLIC HEALTH RELEVANCE: Recent studies have linked oral bacteria to systemic diseases such as pancreatic cancer, diabetes, stroke and heart disease. Although it has yet to be proven that oral bacteria cause these diseases directly, there is some evidence that dental treatment may improve markers of disease. The development of a safe and effective mouthrinse that could remove harmful oral bacteria and potentially reduce the incidence of disease would have a significant impact on public health.
描述(由申请人提供):牙周病最近被确定为导致胰腺癌、心血管疾病(动脉粥样硬化、心肌梗塞和中风)和糖尿病等全身性疾病以及早产等妊娠并发症的发病率和死亡率增加的危险因素。众所周知,牙周病是由牙菌斑生物膜中的微生物引起的。由口腔细菌及其成分引发的炎症反应与牙周组织破坏的发病机制有关,并可能导致全身性疾病的发展。虽然因果关系尚未得到证实,但一些研究表明,口腔健康干预措施可能会影响炎症和疾病的生物标志物。该项目的目标是开发一种处方抗菌漱口水,以减少口腔中的细菌生物负荷并对抗口腔疾病和炎症。目前的口腔冲洗产品要么充满副作用,例如染色和味道改变,限制了它们在急性环境中的使用,要么是无效的。根据初步研究,本文开发的口腔冲洗剂预计比目前可用的处方产品更有效且无副作用。高效口腔冲洗剂的开发可能会对公众健康产生深远影响并取得重大商业成功。这项研究是一项快速通道提案,将第一阶段和第二阶段研究结合在一个申请中。 I 期部分有两个具体目标: 目标 1. 用于临床试验的复合口腔冲洗剂制剂 目标 2. 在牙龈炎症的人体临床试验中评估口腔冲洗剂的剂量反应,并研究对指示全身性疾病的生物标志物的影响。 II 期部分有三个具体目标: 目标 1. 用于临床试验的复合口腔冲洗剂配方 目标 2. 在牙龈炎人体临床试验中评估口腔冲洗剂以满足 FDA 要求并研究对指示全身性疾病的生物标志物的影响。 公共卫生相关性:最近的研究已将口腔细菌与胰腺癌、糖尿病、中风和心脏病等全身性疾病联系起来。尽管尚未证明口腔细菌直接导致这些疾病,但有一些证据表明牙科治疗可以改善疾病标志。开发一种安全有效的漱口水,可以去除有害的口腔细菌,并有可能降低疾病的发病率,将对公众健康产生重大影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Charles J Gauntt其他文献

Charles J Gauntt的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Charles J Gauntt', 18)}}的其他基金

Unique Anti-microbial Rinse to Reduce Oral Inflammation
独特的抗菌冲洗剂可减少口腔炎症
  • 批准号:
    8123164
  • 财政年份:
    2010
  • 资助金额:
    $ 41.04万
  • 项目类别:
Unique Anti-microbial Rinse to Reduce Oral Inflammation
独特的抗菌冲洗剂可减少口腔炎症
  • 批准号:
    7671912
  • 财政年份:
    2009
  • 资助金额:
    $ 41.04万
  • 项目类别:
Novel Therapy to Treat Otitis Media
治疗中耳炎的新疗法
  • 批准号:
    7482156
  • 财政年份:
    2008
  • 资助金额:
    $ 41.04万
  • 项目类别:
Non-Toxic Gel to Treat Vulvovaginal Candidiasis
用于治疗外阴阴道念珠菌病的无毒凝胶
  • 批准号:
    7051865
  • 财政年份:
    2006
  • 资助金额:
    $ 41.04万
  • 项目类别:
Novel Topical Treatment for Postherpetic Neuralgia
带状疱疹后神经痛的新型局部治疗
  • 批准号:
    6991051
  • 财政年份:
    2005
  • 资助金额:
    $ 41.04万
  • 项目类别:
Novel Rinse to Treat Oral Candidiasis in Cancer Patients
治疗癌症患者口腔念珠菌病的新型漱口水
  • 批准号:
    6989894
  • 财政年份:
    2005
  • 资助金额:
    $ 41.04万
  • 项目类别:
Novel Skin Barrier to Prevent and Treat Poison Ivy
预防和治疗毒藤的新型皮肤屏障
  • 批准号:
    6833377
  • 财政年份:
    2004
  • 资助金额:
    $ 41.04万
  • 项目类别:
CHRONIC MYOCARDITIS IN A COXSACKIE VIRUS MURINE MODEL
柯萨奇病毒鼠模型中的慢性心肌炎
  • 批准号:
    2222604
  • 财政年份:
    1991
  • 资助金额:
    $ 41.04万
  • 项目类别:
CHRONIC MYOCARDITIS IN A COXSACKIEVIRUS MURINE MODEL
柯萨奇病毒鼠模型中的慢性心肌炎
  • 批准号:
    3365094
  • 财政年份:
    1991
  • 资助金额:
    $ 41.04万
  • 项目类别:
CHRONIC MYOCARDITIS IN A COXSACKIEVIRUS MURINE MODEL
柯萨奇病毒鼠模型中的慢性心肌炎
  • 批准号:
    3365093
  • 财政年份:
    1991
  • 资助金额:
    $ 41.04万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 41.04万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 41.04万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 41.04万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 41.04万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 41.04万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 41.04万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 41.04万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 41.04万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 41.04万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 41.04万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了